Research & Educational Use Only. Not medical advice. Consult a healthcare professional.
GHRH Analog / Visceral FatEvidence Grade: A (FDA-Approved - Egrifta)
Tesamorelin Protocol Guide
Tesamorelin is a GHRH analog FDA-approved as Egrifta specifically for reducing visceral adipose tissue (VAT). It is the most potent GHRH peptide for targeted visceral fat reduction, stimulating GH release more effectively than sermorelin. Clinical trials demonstrated 15-18% reduction in trunk fat over 26 weeks. This protocol covers reconstitution from a 5mg vial, dosing at 1-2mg daily, visceral fat reduction timeline, and combination with ipamorelin for enhanced GH axis stimulation.
Protocol Overview
- Compound
- Tesamorelin (Egrifta)
- Category
- GHRH Analog (Visceral Fat Targeting)
- Mechanism
- Potent GHRH receptor agonist that stimulates GH release, specifically reducing visceral adipose tissue through lipolytic GH pathways
- MW
- 5,135.9 Da
- Half-Life
- ~26 minutes
- Vial
- 5mg lyophilized
- Route
- Subcutaneous
- Frequency
- 1x daily
- Cycle
- 12-26 weeks
Dosing
| Protocol | Weeks | Dose | Timing |
|---|---|---|---|
| Standard | 1-26 | 2 mg daily | Before bed, fasted |
| Conservative | 1-12 | 1 mg daily | Before bed, fasted |
| With Ipamorelin | 1-16 | 1mg Tesa + 100mcg Ipa | 2x daily, fasted |
Reconstitute 5mg with 2mL BAC water = 2.5mg/mL. 1mg = 40 units, 2mg = 80 units on insulin syringe.
Timeline
Week 1-4
GH and IGF-1 elevation. Sleep quality improvement. Early metabolic changes.
Week 5-12
Measurable visceral fat reduction begins. Body composition improving. Waist circumference decreasing.
Week 13-26
Significant VAT reduction (15-18% in trials). Lipid profile improvements. Sustained body composition benefits.
Side Effects & Stacking
Side Effects
- Injection site reactions (erythema, itching)
- Joint pain / arthralgia
- Peripheral edema
- Paresthesia (tingling)
- Elevated blood glucose (monitor)
Stacking
- Ipamorelin: Synergistic GHRH+GHRP
- Semaglutide: Dual metabolic approach
- AOD-9604: Additional fat metabolism
- MOTS-C: Mitochondrial metabolic support
Blood Work
| Panel | Markers | Timing |
|---|---|---|
| GH Axis | IGF-1 | Baseline, Week 4, 12 |
| Metabolic | Fasting glucose, HbA1c, insulin | Baseline, Week 8, 16 |
| Lipids | Full lipid panel | Baseline, Week 12 |
| Body Comp | DEXA scan (visceral fat) | Baseline, Week 12, 26 |
Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Paid partnership · Learn more